Librede to develop technologies for improving ion channel drug discovery and screening at CNSI incubator

NewsGuard 100/100 Score

Librede Inc. has licensed technology developed by UCLA professor and team

Librede Inc. has joined the UCLA on-campus technology incubator space at the California NanoSystems Institute, where the startup company will work on developing technologies to improve ion channel drug discovery and screening.

Ion channels are proteins in cell membranes that play a central role in generating and transmitting cardiac and neural signals. The channels control the passage of ions into and out of cells; the effects of drugs that act on ion channels can be determined by measuring the flow of ions through these channels. However, conventional measurement technologies, which utilize live cells, are relatively slow and expensive.

A team led by UCLA associate professor of bioengineering Jacob Schmidt has developed a cell-free artificial membrane technology for ion channel measurement that may result in significant savings of time and cost.

This technology has been exclusively licensed by Librede, which was founded in July 2008 by Schmidt and Jason Poulos, Librede's chief technical officer and a co-inventor of the technology. As part of this arrangement, the University of California will earn a royalty on the company's future products.

Librede moved into lab space at the CNSI incubator this month and has access to CNSI core lab facilities such as the Molecular Shared Screening Resource (MSSR) for research and development.

"The CNSI's incubator space is ideal for us," Poulos said. "We have access to state-of-the-art facilities and technical staff that will allow us to rapidly develop our technology and grow our company."

"Although cell-free platforms for ion channel measurement have been used for decades, their cost and expertise requirements have mostly limited their use to scientists," Schmidt said. "We have developed an artificial cell membrane that is inexpensive, easy to use and automatable. We hope that our technology will reduce the cost and time associated with ion channel measurements."

The UCLA on-campus Technology Incubator Program at the CNSI is an innovative resource with a mission to help accelerate the growth of entrepreneurial startup companies and early-stage technology research projects that originate at UCLA. The incubator offers shared, flexible lab space dedicated to housing eight to 10 early-stage incubation projects for short periods of time.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Aspen Biosciences launches Pipeline, the program management software platform specifically for drug discovery. The groundbreaking ‘Pipeline’ Platform is now available for therapeutics development teams